Tamoxifen-associated malignant endometrial tumors: Pathologic features and expression of hormone receptors estrogen-α, estrogen-β and progesterone; A case controlled study

Gynecologic Oncology

Volumn 92, Issue 2, 2004, Pages 553-558

  Wilder, James L ^a   Shajahan, Shahin ^a   Khattar, Nada H ^a   Wilder, Dawn M ^c   Yin, Jianming ^a   Rushing, Rodney S ^a   Beaven, Rick ^a   Kaetzel, Charlotte ^a   Ueland, Frederick R ^a   Van Nagell, John R ^a   Kryscio, Richard J ^a   Lele, Subodh M ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^c NONE

Author keywords

Estrogen ; Estrogen ; Progesterone; TAMET; Tamoxifen associated malignant endometrial tumors

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FORMALDEHYDE; HORMONE RECEPTOR; PARAFFIN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGE; AGED; ARTICLE; BODY WEIGHT; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MICRODISSECTION; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ISOLATION; TISSUE SECTION;

EID: 10744219709     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2003.10.040     Document Type: Article

References (25)

1. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 93:1996;5925-5930.
2. Pettersson K., Gustafsson J.A. Role of estrogen receptor beta in estrogen action. Annu. Rev. Physiol. 63:2001;165-192.
3. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J. et al. Differential ligand activation of estrogen receptors ER-alpha and ER-beta at AP1 sites. Science. 277:1997;1508-1510.
4. Liu M.M., Albanese C., Anderson C.M., Hilty K., Webb P., Uht R.M.et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J. Biol. Chem. 277:2002;24353-24360.
5. Astruc M.E., Chabret C., Bali P., Gagne D., Pons M. Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1 mediated response: involvement of the estrogen receptor. Endocrinology. 136:1995;824-832.
6. Johnston S.R., Lu B., Scott G.K., Kushner P.J., Smith I.E., Dowsett M.et al. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin. Cancer Res. 5:1999;251-256.
7. Dumont J.A., Bitonti A.J., Wallace C.D., Baumann R.J., Cashman E.A., Cross-Doersen D.E. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ. 7:1996;351-359.
8. Speirs V., Malone C., Walton D.S., Kerin M.J., Atkin S.L. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 59:1999;5421-5424.
9. Gatalica Z., Lele S.M., Rampy B.A., Norris B.A. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. Cancer. 88(6):2000;1378-1383.
10. Jemal A., Thomas A., Murray T., Thun M. Cancer statistics, 2002. CA Cancer J. Clin. 52:2002;23-47.
11. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., Cronin W.M. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86:1994;527-537.
12. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet. 351:1998;1451-1467.
13. Osborne C.K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339:1998;1609-1618.
14. Magriples U., Naftolin F., Schwartz P.E., Carcangiu M.L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol. 11:1993;485-490.
15. Mignotte H., Lasset C., Bonadona V., Lesur A., Luporsi E., Rodier J.F.et al. Iatrogenic risk of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int. J. Cancer. 76:1998;325-330.
16. Kloos I., Delaloge S., Pautier P., Di Palma M., Goupil A., Duvillard P. et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and a review of the literature. Int. J. Gynecol. Cancer. 12:2002;496-500.
17. Assikis V.J., Neven P., Jordan V.C., Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur. J. Cancer. 32A:1996;1464-1476.
18. Mourits M.J., De Vries E.G., Willemse P.H., Ten Hoor K.A., Hollema H., Van der Zee A.G. Tamoxifen treatment and gynecologic side effects: a review. Obstet. Gynecol. 97:2001;855-866.
19. Dallenbach-Hellweg G., Schmidt D., Hellberg P., Bourne T., Kreuzwieser E., Doren M.et al. The endometrium in breast cancer patients on tamoxifen. Arch. Gynecol. Obstet. 263:2000;170-177.
20. Muss H.B. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res. Treat. 21:1992;15-26.
21. Takama F., Kanuma T., Wang D., Kagami I., Mizunuma H. Estrogen receptor beta expression and depth of myometrial invasion in human endometrial cancer. Br. J. Cancer. 84:2001;545-549.
22. Saegusa M., Okayasu I. Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2 Status in normal and malignant endometrium. Jpn. J. Cancer Res. 91:2000;510-518.
23. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet. 356:2000;881-887.
24. Schwartz L. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. Eur. J. Cancer. 34(suppl. 4):1998;S23-S24.
25. Fujimoto J., Sakaguchi H., Aoki I., Toyoki H., Tamaya T. Clinical implications of the expression of estrogen receptor-alpha and -beta in primary and metastatic lesions of uterine endometrial cancers. Oncology. 62:2002;269-277.